References
- Abdelgawad IA, Mossallam GI, Radwan NH, Elzawahry HM, Elhifnawy NM (2013). Can glypican3 be diagnostic for early hepatocellular carcinoma among Egyptian patients? Asian Pac J Cancer Prev, 14, 7345-9. https://doi.org/10.7314/APJCP.2013.14.12.7345
- Bertino G, Ardiri AM, Santonocito MM, Boemi PM (2009). Some patients with HCC haven't abnornormal desgamma- carboxy prothrombin and alpha-fetoprotein levels. Panminerva Medica, 51, 133-4.
- Block TM, Comunale MA, Lowman M, et al (2005). Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. PNAS, 102, 779-84. https://doi.org/10.1073/pnas.0408928102
- Bosetti C, Levi F, Boffetta P, et al (2008). Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepatology, 48, 137-45. https://doi.org/10.1002/hep.22312
- Carr BI, Kanke F, Wise M, Satomura S (2007). Clinical evaluation of lens culinaris agglutinin-reactive alphafetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States. Dig Dis Sci, 52, 776-82. https://doi.org/10.1007/s10620-006-9541-2
- Chong RJ, Abdullah MS, Hossain MM, Telisinghe PU, Chong VH (2013). Rising incidence of primary liver cancer in Brunei Darussalam. Asian Pac J Cancer Prev, 14, 3473-7. https://doi.org/10.7314/APJCP.2013.14.6.3473
- Dai X, Zhao HQ, Liu RH, et al (2012). Percutaneous radiofrequency ablation guided by contrast-enhanced ultrasound in treatment of metastatic hepatocellular carcinoma after liver transplantation. Asian Pac J Cancer Prev, 13, 3709-12. https://doi.org/10.7314/APJCP.2012.13.8.3709
- Durazo FA, Blatt LM, Corey WG,, et al (2008). Des-gammacarboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroen Hepatol, 23, 1541-8. https://doi.org/10.1111/j.1440-1746.2008.05395.x
- El-Serag HB, Rudolph KL (2007). Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 132, 2557-76. https://doi.org/10.1053/j.gastro.2007.04.061
- European Association for the Study of the L, European Organisation for R, Treatment of C (2012). EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol, 56, 908-43. https://doi.org/10.1016/j.jhep.2011.12.001
- Fujioka M, Nakashima Y, Nakashima O, Kojiro M (2001). Immunohistologic study on the expressions of alphafetoprotein and protein induced by vitamin K absence or antagonist II in surgically resected small hepatocellular carcinoma. Hepatology, 34, 1128-34. https://doi.org/10.1053/jhep.2001.29202
- Fujiyama S, Tanaka M, Maeda S, et al (2002). Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology, 62, 57-63. https://doi.org/10.1159/000048277
- Garcia M, Ward E, Center M, et al (2007). Global cancer facts & figures 2007. Atlanta, GA: American Cancer Society
- Hu JS, Wu DW, Liang S, Miao XY (2010). GP73, a resident Golgi glycoprotein, is sensibility and specificity for hepatocellular carcinoma of diagnosis in a hepatitis B-endemic Asian population. Med Oncol, 27, 339-45. https://doi.org/10.1007/s12032-009-9215-y
- Ioannou GN, Perkins JD, Carithers RL, (2008). Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology, 134, 1342-51. https://doi.org/10.1053/j.gastro.2008.02.013
- Llovet JM, Bruix J (2000). Early diagnosis and treatment of hepatocellular carcinoma. Best Pract Res Cl Ga, 14, 991-1008. https://doi.org/10.1053/bega.2000.0143
- Llovet JM, Di Bisceglie AM, Bruix J, et al (2008). Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst, 100, 698-711. https://doi.org/10.1093/jnci/djn134
- Mao Y, Yang H, Xu H, et al (2010). Golgi protein 73 (GOLPH2). is a valuable serum marker for hepatocellular carcinoma. Gut, 59, 1687-93. https://doi.org/10.1136/gut.2010.214916
- Marrero JA, Romano PR, Nikolaeva O, et al (2005). GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol, 43, 1007-12. https://doi.org/10.1016/j.jhep.2005.05.028
- Nouso K, Kobayashi Y, Nakamura S, et al (2011). Prognostic importance of fucosylated alpha-fetoprotein in hepatocellular carcinoma patients with low alpha-fetoprotein. J Gastroen Hepatol, 26, 1195-1200. https://doi.org/10.1111/j.1440-1746.2011.06720.x
- Oka H, Saito A, Ito K, et al (2001). Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutininreactive alpha-fetoprotein. J Gastroen Hepatol, 16, 1378-83 https://doi.org/10.1046/j.1440-1746.2001.02643.x
- Parkin DM, Bray F, Ferlay J, Pisani P (2005). Global cancer statistics, 2002. CA-Cancer J Clin, 55, 74-108. https://doi.org/10.3322/canjclin.55.2.74
- Riener MO, Stenner F, Liewen H, et al (2009). Golgi phosphoprotein 2 (GOLPH2). expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology, 49, 1602-09. https://doi.org/10.1002/hep.22843
- Saito Y, Shimada M, Utsunomiya T, et al (2012). Prediction of recurrence of hepatocellular carcinoma after curative hepatectomy using preoperative Lens culinaris agglutininreactive fraction of alpha-fetoprotein. Hepatol Res, 42, 887-94. https://doi.org/10.1111/j.1872-034X.2012.01004.x
- Schutte K, Bornschein J, Malfertheiner P (2009). Hepatocellular carcinoma-epidemiological trends and risk factors. Digest Dis, 27, 80-92.
- Shariff MI, Cox IJ, Gomaa AI, et al (2009). Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroent, 3, 353-67. https://doi.org/10.1586/egh.09.35
- Sterling RK, Wright EC, Morgan TR, et al (2012). Frequency of Elevated Hepatocellular Carcinoma (HCC). Biomarkers in Patients With Advanced Hepatitis C. Am J Gastroenterol, 107, 64-74. https://doi.org/10.1038/ajg.2011.312
- Taketa K, Sekiya C, Namiki M, et al (1990). Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions. Gastroenterology, 99, 508-18. https://doi.org/10.1016/0016-5085(90)91034-4
- Tamura Y, Suda T, Arii S, et al (2013). Value of highly sensitive fucosylated fraction of alpha-fetoprotein for prediction of hepatocellular carcinoma recurrence after curative treatment. Dig Dis Sci, 58, 2406-12. https://doi.org/10.1007/s10620-013-2661-6
- Tangkijvanich P, Anukulkarnkusol N, Suwangool P, et al (2000). Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol, 31, 302-08. https://doi.org/10.1097/00004836-200012000-00007
- Tateishi R, Shiina S, Yoshida H, et al (2006). Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers. Hepatology, 44, 1518-27. https://doi.org/10.1002/hep.21408
- Toyoda H, Kumada T, Kaneoka Y, et al (2008). Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC. J Hepatol, 49, 223-32. https://doi.org/10.1016/j.jhep.2008.04.013
- Toyoda H, Kumada T, Tada T, et al (2011). Clinical utility of highly sensitive Lens culinaris agglutinin-reactive alphafetoprotein in hepatocellular carcinoma patients with alphafetoprotein <20 ng/mL. Cancer Sci, 102, 1025-31. https://doi.org/10.1111/j.1349-7006.2011.01875.x
- Witjes CD, van Aalten SM, Steyerberg EW, et al (2013). Recently introduced biomarkers for screening of hepatocellular carcinoma: a systematic review and meta-analysis. Hepa Inter, 7, 59-64. https://doi.org/10.1007/s12072-012-9374-3
- Yamamoto K, Imamura H, Matsuyama Y, et al (2009). Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy. Ann Surg Oncol, 16, 2795-2804. https://doi.org/10.1245/s10434-009-0618-y
- Yamamoto K, Imamura H, Matsuyama Y, et al (2010). AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol, 45, 1272-82. https://doi.org/10.1007/s00535-010-0278-5
-
Yamashita T, Forgues M, Wang W, et al (2008). EpCAM and
$\alpha$ -fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res, 68, 1451-61. https://doi.org/10.1158/0008-5472.CAN-07-6013 - Yoshida S, Kurokohchi K, Arima K, et al (2002). Clinical significance of lens culinaris agglutinin-reactive fraction of serum alpha-fetoprotein in patients with hepatocellular carcinoma. Int J Oncol, 20, 305-9.
Cited by
- Clinical Significance of Joint Detection of Serum VEGF, SIL-2R and HGF in Patients with Primary Hepatocellular Carcinoma before and after Percutaneous Microwave Coagulation Therapy vol.15, pp.11, 2014, https://doi.org/10.7314/APJCP.2014.15.11.4545
- Differential Expression of IQGAP1/2 in Hepatocellular Carcinoma and its Relationship with Clinical Outcomes vol.15, pp.12, 2014, https://doi.org/10.7314/APJCP.2014.15.12.4951
- Elevated PIVKA-II is Associated with Early Recurrence and Poor Prognosis in BCLC 0-A Hepatocellular Carcinomas vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6673
- Diagnostic value of alpha-fetoprotein-L3 and Golgi protein 73 in hepatocellular carcinomas with low AFP levels vol.35, pp.12, 2014, https://doi.org/10.1007/s13277-014-2506-8
- Abnormal Expression of Golgi Protein 73 in Clinical Values and Their Role in HBV-Related Hepatocellular Carcinoma Diagnosis and Prognosis vol.15, pp.12, 2015, https://doi.org/10.5812/hepatmon.32918
- Estimation of Leucine Aminopeptidase and 5-Nucleotidase Increases Alpha-Fetoprotein Sensitivity in Human Hepatocellular Carcinoma Cases vol.16, pp.3, 2015, https://doi.org/10.7314/APJCP.2015.16.3.959
- Preparation and Characterization of Anti-GP73 Monoclonal Antibodies and Development of Double-antibody Sandwich ELISA vol.16, pp.5, 2015, https://doi.org/10.7314/APJCP.2015.16.5.2043
- Hepatocellular carcinoma: A comprehensive review vol.7, pp.26, 2015, https://doi.org/10.4254/wjh.v7.i26.2648
- Overexpression of CD147 is associated with poor prognosis, tumor cell migration and ERK signaling pathway activation in hepatocellular carcinoma vol.14, pp.3, 2017, https://doi.org/10.3892/etm.2017.4818
- A sensitive three monoclonal antibodies based automatic latex particle-enhanced turbidimetric immunoassay for Golgi protein 73 detection vol.7, pp.1, 2017, https://doi.org/10.1038/srep40090
- Golgi protein 73 and its diagnostic value in liver diseases pp.09607722, 2019, https://doi.org/10.1111/cpr.12538
- Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study vol.119, pp.1, 2018, https://doi.org/10.1038/s41416-018-0103-0